These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11436503)

  • 21. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
    Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
    Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
    Niki T; Iba S; Tokunou M; Yamada T; Matsuno Y; Hirohashi S
    Clin Cancer Res; 2000 Jun; 6(6):2431-9. PubMed ID: 10873096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
    Tobler NE; Detmar M
    J Leukoc Biol; 2006 Oct; 80(4):691-6. PubMed ID: 16793912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma.
    Niki T; Iba S; Yamada T; Matsuno Y; Enholm B; Hirohashi S
    J Pathol; 2001 Apr; 193(4):450-7. PubMed ID: 11276003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.
    Clarijs R; Schalkwijk L; Ruiter DJ; de Waal RM
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1422-8. PubMed ID: 11381041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C].
    Mandriota SJ; Pepper MS
    J Soc Biol; 1999; 193(2):159-63. PubMed ID: 10451350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of tumor lymphangiogenesis in metastatic spread.
    Stacker SA; Baldwin ME; Achen MG
    FASEB J; 2002 Jul; 16(9):922-34. PubMed ID: 12087053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
    Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
    Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y; Opeskin K; Goad J; Williams ED
    Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma.
    Maehara Y; Kabashima A; Koga T; Tokunaga E; Takeuchi H; Kakeji Y; Sugimachi K
    Surgery; 2000 Sep; 128(3):408-16. PubMed ID: 10965312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
    Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
    Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane.
    Oh SJ; Jeltsch MM; Birkenhäger R; McCarthy JE; Weich HA; Christ B; Alitalo K; Wilting J
    Dev Biol; 1997 Aug; 188(1):96-109. PubMed ID: 9245515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
    EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
    Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
    Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathways targeting tumor lymphangiogenesis.
    Wissmann C; Detmar M
    Clin Cancer Res; 2006 Dec; 12(23):6865-8. PubMed ID: 17145802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.